Literature DB >> 7073269

Cefamandole treatment of Salmonella bacteremia.

E M De Carvalho, R Martinelli, M M De Oliveira, H Rocha.   

Abstract

The efficacy of cefamandole in the treatment of 19 patients with salmonella bacteremia was evaluated. Although all of the salmonella strains isolated were highly susceptible to cefamandole in vitro, a therapeutic failure was observed in 7 (36.8%) of the 19 patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7073269      PMCID: PMC181882          DOI: 10.1128/AAC.21.2.334

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro antibiotic susceptibility of salmonellae.

Authors:  F Barros; O M Korzeniowski; M A Sande; K Martins; L C Santos; H Rocha
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

2.  Double-blind trial with chloramphenicol and the combination trimethoprim-sulfamethoxazole in typhoid.

Authors:  N Cardoso
Journal:  S Afr Med J       Date:  1972-09-09

3.  Antibiotic resistance in typhoid fever. Chloramphenicol resistance among clinical isolates of Salmonella typhosa in Los Angeles, 1972--epidemiologic and bacteriologic characteristics.

Authors:  G Overturf; K I Marton; A W Mathies
Journal:  N Engl J Med       Date:  1973-08-30       Impact factor: 91.245

4.  Comparison of parenteral ampicillin and parenteral chloramphenicol in the treatment of typhoid fever.

Authors:  D Kaye; L Eyckmans; H Rocha; A Prata; E W Hook
Journal:  Ann N Y Acad Sci       Date:  1967-09-27       Impact factor: 5.691

5.  Comparison of trimethoprim-sulfamethoxazole and amoxicillin in therapy of chloramphenicol-resistant and chloramphenicol-sensitive typhoid fever.

Authors:  R H Gilman; M Terminel; M M Levine; P Hernandez-Mendosa; E Calderone; V Vasquez; E Martinez; M J Snyder; R B Hornick
Journal:  J Infect Dis       Date:  1975-12       Impact factor: 5.226

6.  Therapy of antimicrobial-resistant typhoid fever.

Authors:  T Butler; N N Linh; K Arnold; M D Adickman; D M Chau; M M Muoi
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

7.  Cefazolin in the treatment of acute enteric fever.

Authors:  M Uwaydah
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

8.  Antimicrobial resistance and R factors in Salmonella isolated in California (1971-1972).

Authors:  M L Bissett; S L Abbott; R M Wood
Journal:  Antimicrob Agents Chemother       Date:  1974-02       Impact factor: 5.191

9.  Antimicrobial activity of cefamandole against Salmonella typhi.

Authors:  S Z Hirschman; B R Meyers; A Miller
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

10.  Salmonella typhi resistant to chloramphenicol, ampicillin, and other antimicrobial agents: strains isolated during an extensive typhoid fever epidemic in Mexico.

Authors:  J Olarte; E Galindo
Journal:  Antimicrob Agents Chemother       Date:  1973-12       Impact factor: 5.191

View more
  4 in total

1.  Treatment of experimental endocarditis due to ampicillin-susceptible or ampicillin-resistant Salmonella enteritidis.

Authors:  M L Fernández Guerrero; R Torres Perea; C Verdejo Morcillo; R Fernández Roblas; M de Górgolas
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

2.  Bactericidal activities of chloramphenicol and eleven other antibiotics against Salmonella spp.

Authors:  S R Preblud; C J Gill; J M Campos
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

3.  Treatment of typhoid fever with cefamandole.

Authors:  M Uwaydah; N T Nassar; H Harakeh; S Vartivarian; A Talhouk; H Kantarjian
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

4.  Invasive non-typhoidal Salmonella infections in sub-Saharan Africa: a systematic review on antimicrobial resistance and treatment.

Authors:  Bieke Tack; Jolien Vanaenrode; Jan Y Verbakel; Jaan Toelen; Jan Jacobs
Journal:  BMC Med       Date:  2020-07-17       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.